Redeye: Idogen - Trying to modify mother nature

Report this content

We are initiating coverage of Idogen, a Swedish early-stage biotech play focused on developing cell therapies. The concept could be used to treat patients by modifying their own immune system and has an attractive commercial potential. But it is still in the very early stages of development and many critical steps remain, hence, the risk level is high.

Read more and download the initial analysis:

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.